Prespecified subgroup analysis of complete response and ORR in the dose-expansion cohort.
DISEASE
a,b, Complete response (CR) rates (Median PFS was 16.5 months (95% CI: 5.6–23.4) in patients who had received one prior line of therapy and 11.4 months (95% CI: 5.7–18.7) in those who had received two or more lines. In patients with DH/THL, median DoR and PFS were 20.5 months (95% CI: 3.0–NE) and 6.2 months (95% CI: 2.6–16.5), respectively. In 35 patients who received prior CAR-T cell therapy in the dose-expansion cohort, the median DoR was NE (95% CI: 8.8–NE), and the median PFS was 9.6 months (95% CI: 4.9–NE). In 26 patients who were refractory to CAR-T cell therapies, the median DoR was 12.5 months (95% CI: 2.8–NE), and the median PFS was 5.7 months (95% CI: 4.3–11.5). In patients with primary refractory disease, median DoR and PFS were 20.5 months (95% CI: 6.7–NE) and 8.5 months (95% CI: 4.9–16.9), respectively.